D. Davila, A. Antoniou, and M. A. Chaudhry, Evaluation of Osseous Metastasis in Bone Scintigraphy, Seminars in Nuclear Medicine, vol.45, issue.1, pp.3-15, 2015.
DOI : 10.1053/j.semnuclmed.2014.07.004

P. Camparo, A. T. Vieillefond, J. E. Madewell, D. A. Podoloff, and G. N. Hortobagyi, Molecular aspects of prostate cancer: Recent data from the literature Bone imaging in metastatic breast cancer, Bull. Cancer J. Clin. Oncol, vol.94, issue.22, pp.77-88, 2004.

S. Paget, The distribution of secondary growths in cancer of the breast. 1889, Cancer Metastasis Rev, vol.8, pp.98-101, 1989.

M. G. Cecchini, A. Wetterwald, G. Van-der-pluijm, G. N. Thalmann, J. T. Buijs et al., Molecular and Biological Mechanisms of Bone Metastasis. EAU Update Ser Osteotropic cancers: From primary tumor to bone Crosstalk between cancer cells and bone microenvironment in bone metastasis, Cancer Lett. Biochem. Biophys. Res. Commun, vol.3, issue.328, pp.214-226, 2005.

R. Ata, C. N. Antonescu, L. Rosivall, I. A. Krizbai, and A. Sebe, Integrins and Cell Metabolism: An Intimate Relationship Impacting Cancer When the endothelium scores an own goal: Endothelial cells actively augment metastatic extravasation through endothelial-mesenchymal transition, Int. J. Mol. Sci. Am. J. Physiol. Heart Circ. Physiol, vol.18, pp.310-1055, 2016.

D. A. Sipkins, X. Wei, J. W. Wu, J. M. Runnels, D. Cote et al., In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment, Nature, vol.166, issue.7044, pp.969-973, 2005.
DOI : 10.4049/jimmunol.166.8.5027

J. Iddon, G. Byrne, and N. J. Bundred, Bone metastasis in breast cancer: the role of parathyroid hormone related protein, Surgical Oncology, vol.8, issue.1, pp.13-25, 1999.
DOI : 10.1016/S0960-7404(99)00011-0

C. A. Klein, Parallel progression of primary tumours and metastases, Nature Reviews Cancer, vol.12, issue.4, pp.302-312, 2009.
DOI : 10.1038/bjc.1988.4

G. Klein, Foulds' Dangerous Idea Revisited: The Multistep Development of Tumors 40 Years Later, Adv. Cancer Res, vol.72, pp.1-23, 1998.
DOI : 10.1016/S0065-230X(08)60698-3

E. R. Fearon and B. Vogelstein, A genetic model for colorectal tumorigenesis, Cell, vol.61, issue.5, pp.759-767, 1990.
DOI : 10.1016/0092-8674(90)90186-I

J. Cairns, Mutation selection and the natural history of cancer, Nature, vol.11, issue.5505, pp.197-200, 1975.
DOI : 10.1159/000391387

M. Olivier, A. Langerod, P. Carrieri, J. Bergh, S. Klaar et al., The Clinical Value of Somatic TP53 Gene Mutations in 1,794 Patients with Breast Cancer, Clinical Cancer Research, vol.12, issue.4, pp.1157-1167, 2006.
DOI : 10.1158/1078-0432.CCR-05-1029

S. S. Mcallister, A. M. Gifford, A. L. Greiner, S. P. Kelleher, M. P. Saelzler et al., Systemic Endocrine Instigation of Indolent Tumor Growth Requires Osteopontin, Cell, vol.133, issue.6, pp.994-1005, 2008.
DOI : 10.1016/j.cell.2008.04.045

S. Koscielny, M. Tubiana, M. G. Le, A. J. Valleron, H. Mouriesse et al., Breast cancer: Relationship between the size of the primary tumour and the probability of metastatic dissemination, British Journal of Cancer, vol.49, issue.6, pp.709-715, 1984.
DOI : 10.1038/bjc.1984.112

S. Koscielny and M. Tubiana, Parallel progression of tumour and metastases, Nature Reviews Cancer, vol.9, issue.2, p.156, 2010.
DOI : 10.1016/S0360-3016(98)00424-6

V. P. Collins, R. K. Loeffler, and H. Tivey, Observations on growth rates of human tumors, Am. J. Roentgenol. Radium Ther. Nucl. Med, vol.76, pp.988-1000, 1956.

Y. Husemann, J. B. Geigl, F. Schubert, P. Musiani, M. Meyer et al., Systemic Spread Is an Early Step in Breast Cancer, Cancer Cell, vol.13, issue.1, pp.58-68, 2008.
DOI : 10.1016/j.ccr.2007.12.003

K. Podsypanina, Y. C. Du, M. Jechlinger, L. J. Beverly, D. Hambardzumyan et al., Seeding and Propagation of Untransformed Mouse Mammary Cells in the Lung, Science, vol.7, issue.11, pp.1841-1844, 2008.
DOI : 10.1038/nrc2256
URL : http://europepmc.org/articles/pmc2694414?pdf=render

O. Schmidt-kittler, T. Ragg, A. Daskalakis, M. Granzow, A. Ahr et al.,

J. Diebold, H. Arnholdt, and P. Muller, From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression, Proc. Natl. Acad. Sci. USA 2003, pp.7737-7742

C. Tomuleasa, F. Zaharie, M. S. Muresan, L. Pop, Z. Fekete et al., How to Diagnose and Treat a Cancer of Unknown Primary Site, J. Gastrointestin. Liver Dis, vol.26, pp.69-79, 2017.

R. N. Kaplan, B. Psaila, and D. Lyden, Bone marrow cells in the ???pre-metastatic niche???: within bone and beyond, Cancer and Metastasis Reviews, vol.441, issue.4, pp.521-529, 2006.
DOI : 10.4049/jimmunol.167.8.4747

K. R. Hess, G. R. Varadhachary, S. H. Taylor, W. Wei, M. N. Raber et al., Metastatic patterns in adenocarcinoma, Cancer, vol.91, issue.7, pp.1624-1633, 2006.
DOI : 10.1016/S0002-9440(10)63090-8

B. Psaila and D. Lyden, The metastatic niche: adapting the foreign soil, Nature Reviews Cancer, vol.3, issue.4, pp.285-293, 2009.
DOI : 10.4161/cc.5.11.2775

D. X. Nguyen, P. D. Bos, and J. Massague, Metastasis: from dissemination to organ-specific colonization, Nature Reviews Cancer, vol.100, issue.4, pp.274-284, 2009.
DOI : 10.1016/S0002-9440(10)65628-3

I. J. Fidler, The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited, Nature Reviews Cancer, vol.122, issue.6, pp.453-458, 2003.
DOI : 10.1016/S0065-230X(08)60034-2

G. P. Gupta, A. J. Minn, Y. Kang, P. M. Siegel, I. Serganova et al., Identifying Site-specific Metastasis Genes and Functions, Cold Spring Harbor Symposia on Quantitative Biology, vol.365, issue.0, pp.149-158, 2005.
DOI : 10.1038/415530a

T. Ara and Y. A. Declerck, Interleukin-6 in bone metastasis and cancer progression, European Journal of Cancer, vol.46, issue.7, pp.1223-1231, 2010.
DOI : 10.1016/j.ejca.2010.02.026

J. Ewing, Neoplastic Diseases: A Treatise on Tumors, 1928.

A. C. Chiang and J. Massague, Molecular Basis of Metastasis, New England Journal of Medicine, vol.359, issue.26, pp.2814-2823, 2008.
DOI : 10.1056/NEJMra0805239

L. R. Zarour, S. Anand, K. G. Billingsley, W. H. Bisson, A. Cercek et al., Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions, Cellular and Molecular Gastroenterology and Hepatology, vol.3, issue.2, pp.163-173
DOI : 10.1016/j.jcmgh.2017.01.006
URL : http://www.cmghjournal.org/article/S2352345X17300115/pdf

D. J. Waugh and C. Wilson, The Interleukin-8 Pathway in Cancer, Clinical Cancer Research, vol.14, issue.21, pp.6735-6741, 2008.
DOI : 10.1158/1078-0432.CCR-07-4843

U. H. Weidle, F. Birzele, G. Kollmorgen, and R. Ruger, Molecular Mechanisms of Bone Metastasis, Cancer Genom. Proteom, vol.13, pp.1-12, 2016.

T. Goerge, A. Barg, E. M. Schnaeker, B. Poppelmann, V. Shpacovitch et al., Tumor-Derived Matrix Metalloproteinase-1 Targets Endothelial Proteinase-Activated Receptor 1 Promoting Endothelial Cell Activation, Cancer Research, vol.66, issue.15, pp.7766-7774, 2006.
DOI : 10.1158/0008-5472.CAN-05-3897
URL : http://cancerres.aacrjournals.org/content/66/15/7766.full.pdf

A. Jacobson and J. L. Cunningham, Connective tissue growth factor in tumor pathogenesis, Fibrogenesis & Tissue Repair, vol.5, issue.Suppl 1
DOI : 10.1038/mt.2010.34

C. Sotiriou, M. Lacroix, L. Lespagnard, D. Larsimont, M. Paesmans et al., Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases, Cancer Letters, vol.169, issue.1, pp.87-95, 2001.
DOI : 10.1016/S0304-3835(01)00524-9

A. A. Rose, F. Pepin, C. Russo, J. E. Abou-khalil, M. Hallett et al., Osteoactivin Promotes Breast Cancer Metastasis to Bone, Molecular Cancer Research, vol.5, issue.10, pp.1001-1014, 2007.
DOI : 10.1158/1541-7786.MCR-07-0119
URL : http://mcr.aacrjournals.org/content/molcanres/5/10/1001.full.pdf

B. Psaila and D. Lyden, Roberts, I. Megakaryocytes, malignancy and bone marrow vascular niches, J. Thromb. Haemost, vol.2012, issue.10, pp.177-188

T. A. Guise, G. R. Mundy, . Cancer, and . Bone, Endocr. Rev, vol.19, pp.18-54, 1998.

P. Msaouel, N. Pissimissis, A. Halapas, and M. Koutsilieris, Mechanisms of bone metastasis in prostate cancer: clinical implications, Best Practice & Research Clinical Endocrinology & Metabolism, vol.22, issue.2, pp.341-355, 2008.
DOI : 10.1016/j.beem.2008.01.011

D. F. Quail and J. A. Joyce, Microenvironmental regulation of tumor progression and metastasis, Nature Medicine, vol.87, issue.11, pp.1423-1437
DOI : 10.1016/j.ccr.2013.02.013

J. T. Buijs, K. R. Stayrook, and T. A. Guise, The role of TGF-beta in bone metastasis: Novel therapeutic perspectives. Bonekey Rep, p.96, 2012.

P. Juarez and T. A. Guise, TGF-?? in cancer and bone: Implications for treatment of bone metastases, Bone, vol.48, issue.1, pp.23-29, 2011.
DOI : 10.1016/j.bone.2010.08.004

T. Kiriyama, M. T. Gillespie, J. A. Glatz, S. Fukumoto, J. M. Moseley et al., Transforming growth factor ?? stimulation of parathyroid hormone-related protein (PTHrP): A paracrine regulator?, Molecular and Cellular Endocrinology, vol.92, issue.1, pp.55-62, 1993.
DOI : 10.1016/0303-7207(93)90074-T

L. A. Kingsley, P. G. Fournier, J. M. Chirgwin, and T. A. Guise, Molecular Biology of Bone Metastasis, Molecular Cancer Therapeutics, vol.6, issue.10, pp.2609-2617, 2007.
DOI : 10.1158/1535-7163.MCT-07-0234

S. Mcmahon, M. Charbonneau, S. Grandmont, D. E. Richard, and C. M. Dubois, Transforming Growth Factor ??1 Induces Hypoxia-inducible Factor-1 Stabilization through Selective Inhibition of PHD2 Expression, Journal of Biological Chemistry, vol.75, issue.34, pp.24171-24181, 2006.
DOI : 10.1002/1097-0142(20010301)91:5<964::AID-CNCR1086>3.0.CO;2-O

A. Moustakas and C. H. Heldin, Induction of epithelial-mesenchymal transition by transforming growth factor beta, Semin. Cancer Biol, vol.2012, issue.22, pp.446-454

R. A. Flavell, S. Sanjabi, S. H. Wrzesinski, and P. Licona-limon, The polarization of immune cells in the tumour environment by TGF??, Nature Reviews Immunology, vol.7, issue.8, pp.554-567, 2010.
DOI : 10.1172/JCI200215333

T. Yoneda, K. Hata, M. Nakanishi, M. Nagae, T. Nagayama et al., Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain, Bone, vol.48, issue.1, pp.100-105, 2011.
DOI : 10.1016/j.bone.2010.07.009

X. T. Xu, B. Xu, Q. B. Song, and H. Zeng, The role of neural-related factors in the metastasis of the gastrointestinal cancer, J. Cancer Res. Ther, vol.2013, issue.9, pp.123-128

F. Artacho-cordon, S. Rios-arrabal, and P. C. Lara, Matrix metalloproteinases: Potential therapy to prevent the development of second malignancies after breast radiotherapy, Surgical Oncology, vol.21, issue.3, pp.143-151, 2012.
DOI : 10.1016/j.suronc.2012.06.001

R. Leblanc, S. C. Lee, M. David, J. C. Bordet, D. D. Norman et al., Interaction of platelet-derived autotaxin with tumor integrin ??V??3 controls metastasis of breast cancer cells to bone, Blood, vol.124, issue.20, pp.3141-3150, 2014.
DOI : 10.1182/blood-2014-04-568683

O. Peyruchaud, R. Leblanc, and M. David, Pleiotropic activity of lysophosphatidic acid in bone metastasis, Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol.1831, issue.1, pp.99-104, 2013.
DOI : 10.1016/j.bbalip.2012.06.004

K. N. Weilbaecher, T. A. Guise, and L. K. Mccauley, Cancer to bone: a fatal attraction, Nature Reviews Cancer, vol.71, issue.6, pp.411-425, 2011.
DOI : 10.1158/0008-5472.CAN-10-1708
URL : http://europepmc.org/articles/pmc3666847?pdf=render

E. Voronov, D. S. Shouval, Y. Krelin, E. Cagnano, D. Benharroch et al., IL-1 is required for tumor invasiveness and angiogenesis, Proc. Natl. Acad. Sci. USA 2003, pp.2645-2650
DOI : 10.1002/art.10546

D. Francesco, S. Castellan, P. Manco, R. Tenaglia, and R. L. , Reciprocal cross-talk between Prostaglandin E2 and bone in prostate cancer: a current review, Central European Journal of Urology, vol.64, pp.201-204, 2011.
DOI : 10.5173/ceju.2011.04.art2

M. J. Diament, M. I. Stillitani, L. Puricelli, E. Bal-de-kier-joffe, and S. Klein, GM-CSF secreted by murine adenocarcinoma cells modulates tumor progression and immune activity, Oncology Reports, vol.10, pp.1647-1652, 2003.
DOI : 10.3892/or.10.5.1647

H. Kato, H. Wakabayashi, Y. Naito, S. Kato, T. Nakagawa et al., Anti-Tumor Necrosis Factor Therapy Inhibits Lung Metastasis in an Osteosarcoma Cell Line, Oncology, vol.88, issue.3, pp.139-146, 2015.
DOI : 10.1159/000368414

U. Verbovsek, C. J. Van-noorden, and T. Lah, Complexity of cancer protease biology: Cathepsin K expression and function in cancer progression, Seminars in Cancer Biology, vol.35, pp.71-84, 2015.
DOI : 10.1016/j.semcancer.2015.08.010

T. E. Kruger, A. H. Miller, A. K. Godwin, and J. Wang, Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers, Critical Reviews in Oncology/Hematology, vol.89, issue.2, pp.330-341, 2014.
DOI : 10.1016/j.critrevonc.2013.08.013
URL : http://europepmc.org/articles/pmc3946954?pdf=render

H. Davis, E. Raja, K. Miyazono, and Y. Tsubakihara, Mechanisms of action of bone morphogenetic proteins in cancer, Cytokine & Growth Factor Reviews, vol.27, pp.81-92, 2016.
DOI : 10.1016/j.cytogfr.2015.11.009

K. C. Valkenburg, M. R. Steensma, B. O. Williams, and Z. Zhong, Skeletal metastasis: treatments, mouse models, and the Wnt signaling, Chinese Journal of Cancer, vol.32, issue.7, pp.380-396, 2013.
DOI : 10.5732/cjc.012.10218
URL : http://www.cjcsysu.cn/cn/entopdf.asp?ly=CJC&idno=20326

J. T. Buijs, C. C. Kuijpers, and G. Van-der-pluijm, Targeted Therapy Options for Treatment of Bone Metastases; Beyond Bisphosphonates, Current Pharmaceutical Design, vol.16, issue.27, pp.3015-3027, 2010.
DOI : 10.2174/138161210793563536

K. Garrison, T. Hahn, W. C. Lee, L. E. Ling, A. D. Weinberg et al., The small molecule TGF-beta signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis, Cancer Immunol. Immunother, pp.61-511, 2012.
DOI : 10.1007/s00262-011-1119-y
URL : http://europepmc.org/articles/pmc3595193?pdf=render

R. E. Coleman, Skeletal complications of malignancy, Cancer, vol.12, issue.S8, pp.1588-1594, 1997.
DOI : 10.1016/8756-3282(91)90066-R
URL : http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G/pdf

K. Liepe and J. Kotzerke, Internal radiotherapy of painful bone metastases, Methods, vol.55, issue.3, pp.258-270, 2011.
DOI : 10.1016/j.ymeth.2011.07.001

A. N. Kurup and M. R. Callstrom, Expanding role of percutaneous ablative and consolidative treatments for musculoskeletal tumours, Clinical Radiology, vol.72, issue.8, pp.645-656
DOI : 10.1016/j.crad.2017.02.019

M. Szendroi, I. Antal, A. Szendroi, A. Lazary, and P. P. Varga, Diagnostic algorithm, prognostic factors and surgical treatment of metastatic cancer diseases of the long bones and spine, EFORT Open Reviews, vol.2, issue.9, pp.372-381, 2017.
DOI : 10.1302/2058-5241.2.170006

J. Thariat, S. Vignot, R. J. Bensadoun, and F. Mornex, Improvements of ablative local treatments modify the management of the oligometastatic disease. Cancer Radiother, pp.325-329, 2012.

A. Kougioumtzopoulou, A. Zygogianni, Z. Liakouli, E. Kypraiou, and V. Kouloulias, The role of radiotherapy in bone metastases: A critical review of current literature, European Journal of Cancer Care, vol.15, issue.4, 2017.
DOI : 10.1007/s10147-010-0074-5

J. Chiras, E. Shotar, E. Cormier, and F. Clarencon, Interventional radiology in bone metastases, European Journal of Cancer Care, vol.21, issue.6, 2017.
DOI : 10.1007/s00540-007-0498-x

J. D. Laredo, J. Chiras, S. Kemel, L. Taihi, and B. Hamze, Vertebroplasty and interventional radiology procedures for bone metastases, Joint Bone Spine, vol.85, issue.2, 2017.
DOI : 10.1016/j.jbspin.2017.05.005

S. Pikis, J. Goldstein, and S. Spektor, Potential neurotoxic effects of polymethylmethacrylate during cranioplasty, Journal of Clinical Neuroscience, vol.22, issue.1, pp.139-143, 2015.
DOI : 10.1016/j.jocn.2014.06.006

M. Ratasvuori, R. Wedin, J. Keller, M. Nottrott, O. Zaikova et al., Insight opinion to surgically treated metastatic bone disease: Scandinavian Sarcoma Group Skeletal Metastasis Registry report of 1195 operated skeletal metastasis, Surgical Oncology, vol.22, issue.2, pp.132-138, 2013.
DOI : 10.1016/j.suronc.2013.02.008

M. Van-driel and J. Van-leeuwen, Cancer and bone: A complex complex, Archives of Biochemistry and Biophysics, vol.561, issue.561, pp.159-166
DOI : 10.1016/j.abb.2014.07.013

G. R. Mundy, Metastasis to bone: causes, consequences and therapeutic opportunities, Nature Reviews Cancer, vol.87, issue.Suppl. 1, pp.584-593, 2002.
DOI : 10.1093/jnci/87.21.1588

X. Zou, L. Zou, Y. He, and C. Bunger, Molecular treatment strategies and surgical reconstruction for metastatic bone diseases, Cancer Treatment Reviews, vol.34, issue.6, pp.527-538, 2008.
DOI : 10.1016/j.ctrv.2008.03.012

E. Verron and J. M. Bouler, Is bisphosphonate therapy compromised by the emergence of adverse bone disorders? Drug Discov, Today 2014, vol.19, pp.312-319
DOI : 10.1016/j.drudis.2013.08.010

G. Bernardini, A. Gismondi, and A. Santoni, Chemokines and NK cells: Regulators of development, trafficking and functions, Immunology Letters, vol.145, issue.1-2, pp.39-46
DOI : 10.1016/j.imlet.2012.04.014
URL : https://hal.archives-ouvertes.fr/pasteur-00966455

N. Gronich and G. Rennert, Beyond aspirin???cancer prevention with statins, metformin and bisphosphonates, Nature Reviews Clinical Oncology, vol.102, issue.11, pp.625-642, 2013.
DOI : 10.1038/sj.bjc.6605555

G. Odri, P. P. Kim, F. Lamoureux, C. Charrier, S. Battaglia et al., Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing???s sarcoma via inhibition of cell migration, BMC Cancer, vol.15, issue.6, p.169, 2014.
DOI : 10.1634/theoncologist.2010-0093

P. Clezardin, F. H. Ebetino, and P. G. Fournier, Bisphosphonates and Cancer-Induced Bone Disease: Beyond Their Antiresorptive Activity: Figure 1., Cancer Research, vol.65, issue.12, pp.4971-4974, 2005.
DOI : 10.1158/0008-5472.CAN-05-0264

T. A. Guise, Antitumor effects of bisphosphonates: Promising preclinical evidence, Cancer Treatment Reviews, vol.34, pp.19-24, 2008.
DOI : 10.1016/j.ctrv.2008.03.006

P. Clezardin, Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities, BoneKEy Reports, vol.2, 2013.
DOI : 10.1038/bonekey.2013.1

I. Benzaid, H. Monkkonen, E. Bonnelye, J. Monkkonen, and P. Clezardin, In Vivo Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Trigger V??9V??2 T-cell Antitumor Cytotoxicity through ICAM-1 Engagement, Clinical Cancer Research, vol.18, issue.22, pp.6249-6259, 2012.
DOI : 10.1158/1078-0432.CCR-12-0918
URL : http://clincancerres.aacrjournals.org/content/clincanres/18/22/6249.full.pdf

I. Benzaid, H. Monkkonen, V. Stresing, E. Bonnelye, J. Green et al., High Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Promote V??9V??2 T-Cell Chemotaxis and Cytotoxicity In Vivo, Cancer Research, vol.71, issue.13, pp.4562-4572, 2011.
DOI : 10.1158/0008-5472.CAN-10-3862
URL : http://cancerres.aacrjournals.org/content/canres/71/13/4562.full.pdf

L. J. Dominguez, G. Di-bella, M. Belvedere, and M. Barbagallo, Physiology of the aging bone and mechanisms of action of bisphosphonates, Biogerontology, vol.95, issue.5, pp.397-408, 2011.
DOI : 10.1073/pnas.95.7.3597

V. Hirsh, N. S. Tchekmedyian, L. S. Rosen, M. Zheng, and Y. J. Hei, Clinical Benefit of Zoledronic Acid in Patients with Lung Cancer and OtherSolid Tumors: Analysis Based on History of Skeletal Complications, Clinical Lung Cancer, vol.6, issue.3, pp.170-174, 2004.
DOI : 10.3816/CLC.2004.n.030

F. Saad, D. M. Gleason, R. Murray, S. Tchekmedyian, P. Venner et al., Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer, JNCI Journal of the National Cancer Institute, vol.21, issue.21, pp.879-882, 2004.
DOI : 10.1200/JCO.2003.08.017

E. Terpos, C. B. Confavreux, and P. Clezardin, Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma, BoneKEy Reports, vol.4
DOI : 10.1038/bonekey.2015.113

C. H. Van-poznak, J. H. Von-roenn, and S. Temin, American Society of Clinical Oncology Clinical Practice Guideline Update: Recommendations on the Role of Bone-Modifying Agents in Metastatic Breast Cancer, Journal of Oncology Practice, vol.7, issue.2, pp.117-121, 2011.
DOI : 10.1200/JOP.2011.000212

R. Coleman, M. Gnant, G. Morgan, and P. Clezardin, Effects of Bone-Targeted Agents on Cancer Progression and Mortality, JNCI Journal of the National Cancer Institute, vol.12, issue.12, pp.1059-1067
DOI : 10.1016/S1470-2045(11)70033-X
URL : https://academic.oup.com/jnci/article-pdf/104/14/1059/7673903/djs263.pdf

S. Khosla, D. Burr, J. Cauley, D. W. Dempster, P. R. Ebeling et al., Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research, Journal of Bone and Mineral Research, vol.106, issue.S1, pp.1479-1491, 2007.
DOI : 10.14219/jada.archive.2005.0110

F. Lezot, J. Chesneau, S. Battaglia, R. Brion, B. Castaneda et al., Preclinical evidence of potential craniofacial adverse effect of zoledronic acid in pediatric patients with bone malignancies, Bone, vol.68, pp.146-152, 2014.
DOI : 10.1016/j.bone.2014.08.018

P. Anderson, L. Kopp, N. Anderson, K. Cornelius, C. Herzog et al., Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma), Expert Opinion on Investigational Drugs, vol.5, issue.11, pp.1703-1715, 2008.
DOI : 10.1083/jcb.124.4.619

D. Antonio, C. Passaro, A. Gori, B. Del-signore, E. Migliorino et al., Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies, Therapeutic Advances in Medical Oncology, vol.29, issue.1, pp.101-114
DOI : 10.1002/ijc.24470

M. Clemons, K. A. Gelmon, K. I. Pritchard, and A. H. Paterson, Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art, Current Oncology, vol.19, issue.5, pp.259-268
DOI : 10.3747/co.19.1011

P. Peddi, M. A. Lopez-olivo, G. F. Pratt, and M. E. Suarez-almazor, Denosumab in patients with cancer and skeletal metastases: A systematic review and meta-analysis, Cancer Treatment Reviews, vol.39, issue.1, pp.97-104, 2013.
DOI : 10.1016/j.ctrv.2012.07.002
URL : http://europepmc.org/articles/pmc3691016?pdf=render

P. D. Miller, M. A. Bolognese, E. M. Lewiecki, M. R. Mcclung, B. Ding et al., Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial, Bone, vol.43, issue.2, pp.222-229, 2008.
DOI : 10.1016/j.bone.2008.04.007

S. Casimiro, T. A. Guise, and J. Chirgwin, The critical role of the bone microenvironment in cancer metastases, Molecular and Cellular Endocrinology, vol.310, issue.1-2, pp.71-81, 2009.
DOI : 10.1016/j.mce.2009.07.004

K. Ando, M. F. Heymann, V. Stresing, K. Mori, F. Redini et al., Current Therapeutic Strategies and Novel Approaches in Osteosarcoma, Cancers, vol.2012, issue.4, pp.591-616, 2013.
DOI : 10.1155/2012/523432
URL : http://www.mdpi.com/2072-6694/5/2/591/pdf

S. Fili, M. Karalaki, and B. Schaller, Mechanism of bone metastasis: The role of osteoprotegerin and of the host-tissue microenvironment-related survival factors, Cancer Letters, vol.283, issue.1, pp.10-19, 2009.
DOI : 10.1016/j.canlet.2009.01.011

Y. Wittrant, S. Theoleyre, C. Chipoy, M. Padrines, F. Blanchard et al., New therapeutic targets in bone tumours and associated osteolysis, Biochim. Biophys. Acta, vol.1704, pp.49-57, 2004.
DOI : 10.1016/j.bbcan.2004.05.002
URL : https://hal.archives-ouvertes.fr/inserm-00669006

E. Verron, A. Loubat, G. F. Carle, C. Vignes-colombeix, I. Strazic et al., Molecular effects of gallium on osteoclastic differentiation of mouse and human monocytes, Biochemical Pharmacology, vol.83, issue.5, pp.671-679, 2012.
DOI : 10.1016/j.bcp.2011.12.015
URL : https://hal.archives-ouvertes.fr/hal-00761136

S. Geljic, I. Melis, N. Boukhechba, F. Schaub, S. Mellier et al., Gallium enhances reconstructive properties of a calcium phosphate bone biomaterial, J. Tissue Eng. Regen. Med, 2017.

I. Strazic-geljic, I. Guberovic, B. Didak, H. Schmid-antomarchi, A. Schmid-alliana et al., Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases, Biochemical Pharmacology, vol.116, pp.11-21, 2016.
DOI : 10.1016/j.bcp.2016.06.020

J. C. Scimeca and E. Verron, The multiple therapeutic applications of miRNAs for bone regenerative medicine, Drug Discovery Today, vol.22, issue.7, pp.1084-1091
DOI : 10.1016/j.drudis.2017.04.007

D. Green, I. Mohorianu, I. Mcnamara, T. Dalmay, and W. Fraser, miR-16 is highly expressed in Paget???s associated osteosarcoma, Endocrine-Related Cancer, vol.2, issue.5, pp.27-31, 2017.
DOI : 10.1515/mngs-2015-0001

D. Merkerova, M. Krejcik, Z. Votavova, H. Belickova, M. Vasikova et al., Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome, European Journal of Human Genetics, vol.20, issue.3, pp.313-319
DOI : 10.1111/j.1751-553X.2008.01056.x
URL : https://hal.archives-ouvertes.fr/hal-00598940

H. L. Zhang, X. J. Qin, D. L. Cao, Y. Zhu, X. D. Yao et al., An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions, Asian Journal of Andrology, vol.15, issue.2, pp.231-235, 2013.
DOI : 10.1038/aja.2012.116
URL : http://www.asiaandro.com/news/upload/20130912-aja2012116a.pdf

J. Y. Krzeszinski, W. Wei, H. Huynh, Z. Jin, X. Wang et al., miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2, Nature, vol.40, issue.7515, pp.431-435, 2014.
DOI : 10.1038/ng.2007.30
URL : http://europepmc.org/articles/pmc4149606?pdf=render

S. Colak, Ten Dijke, P. Targeting TGF-beta Signaling in Cancer, Trends Cancer, vol.2017, issue.3, pp.56-71

S. Herbertz, J. S. Sawyer, A. J. Stauber, I. Gueorguieva, K. E. Driscoll et al., Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway, pp.4479-4499

T. A. Guise and K. S. Mohammad, Endothelins in Bone Cancer Metastases, Cancer Treat. Res, vol.118, pp.197-212, 2004.
DOI : 10.1007/978-1-4419-9129-4_9

L. Qiao, Y. Liang, N. Li, X. Hu, D. Luo et al., Endothelin-A receptor antagonists in prostate cancer treatment-a meta-analysis, Int. J. Clin. Exp. Med, vol.8, pp.3465-3473, 2015.

M. H. Bae, S. H. Oh, C. J. Park, B. R. Lee, Y. J. Kim et al., VLA-4 and CXCR4 expression levels show contrasting prognostic impact (favorable and unfavorable, respectively) in acute myeloid leukemia, Annals of Hematology, vol.22, issue.6, pp.1631-1638, 2015.
DOI : 10.1200/JCO.2004.07.131

Z. Liang, Y. Yoon, J. Votaw, M. M. Goodman, L. Williams et al., Silencing of CXCR4 blocks breast cancer metastasis, Cancer Res, vol.65, pp.967-971, 2005.

Z. Wu, K. S. Mcroberts, and D. Theodorescu, The role of PTEN in prostate cancer cell tropism to the bone micro-environment, Carcinogenesis, vol.278, issue.Pt 7, pp.1393-1400, 2007.
DOI : 10.1074/jbc.M304494200

O. Peyruchaud, C. M. Serre, R. Nicamhlaoibh, P. Fournier, and P. Clezardin, Angiostatin Inhibits Bone Metastasis Formation in Nude Mice through a Direct Anti-osteoclastic Activity, Journal of Biological Chemistry, vol.62, issue.46, pp.45826-45832, 2003.
DOI : 10.1677/joe.0.1650587
URL : http://www.jbc.org/content/278/46/45826.full.pdf

J. Y. Krzeszinski and Y. Wan, New therapeutic targets for cancer bone metastasis, Trends in Pharmacological Sciences, vol.36, issue.6, pp.360-373
DOI : 10.1016/j.tips.2015.04.006
URL : http://europepmc.org/articles/pmc4461455?pdf=render

V. L. Malisetty, V. Penugurti, P. Panta, S. K. Chitta, and B. Manavathi, MTA1 expression in human cancers ??? Clinical and pharmacological significance, Biomedicine & Pharmacotherapy, vol.95, issue.95, pp.956-964
DOI : 10.1016/j.biopha.2017.09.025

A. N. Lozano-ondoua, A. M. Symons-liguori, and T. W. Vanderah, Cancer-induced bone pain: Mechanisms and models, Neuroscience Letters, vol.557, pp.52-59, 2013.
DOI : 10.1016/j.neulet.2013.08.003
URL : http://europepmc.org/articles/pmc4542064?pdf=render

P. Honore, N. M. Luger, M. A. Sabino, M. J. Schwei, S. D. Rogers et al., Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord, Nat. Med, vol.6, pp.521-528, 2000.

M. Chwistek, Recent advances in understanding and managing cancer pain, F1000Research, vol.3, p.945, 2017.
DOI : 10.1596/978-1-4648-0349-9_ch9
URL : https://doi.org/10.12688/f1000research.10817.1

Y. Itatani, K. Kawada, S. Inamoto, T. Yamamoto, R. Ogawa et al., The Role of Chemokines in Promoting Colorectal Cancer Invasion/Metastasis, International Journal of Molecular Sciences, vol.487, issue.5, p.17, 2016.
DOI : 10.1038/nature11252

O. 'hayre, M. Salanga, C. L. Handel, T. M. Allen, and S. J. , Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment, Biochemical Journal, vol.409, issue.3, pp.635-649, 2008.
DOI : 10.1042/BJ20071493

B. J. Rollins, Inflammatory chemokines in cancer growth and progression, European Journal of Cancer, vol.42, issue.6, pp.760-767, 2006.
DOI : 10.1016/j.ejca.2006.01.002

P. J. Sarvaiya, D. Guo, I. Ulasov, P. Gabikian, and M. S. Lesniak, Chemokines in tumor progression and metastasis, Oncotarget, vol.4, issue.12, pp.2171-2185, 2013.
DOI : 10.18632/oncotarget.1426

A. P. Vicari and C. Caux, Chemokines in cancer, Cytokine & Growth Factor Reviews, vol.13, issue.2, pp.143-154, 2002.
DOI : 10.1016/S1359-6101(01)00033-8

M. Santoni, S. Bracarda, M. Nabissi, F. Massari, A. Conti et al., Cascinu, S. CXC and CC chemokines as angiogenic modulators in nonhaematological tumors, Biomed. Res. Int, p.768758, 2014.

C. Stockmann, D. Schadendorf, and R. Klose, Helfrich, I. The impact of the immune system on tumor: Angiogenesis and vascular remodeling, Front. Oncol, vol.4, p.69, 2014.

Y. Wang, Y. Xie, and D. Oupicky, Potential of CXCR4/CXCL12 Chemokine Axis in Cancer Drug Delivery, Current Pharmacology Reports, vol.277, issue.27, pp.1-10
DOI : 10.1074/jbc.M200889200
URL : https://link.springer.com/content/pdf/10.1007%2Fs40495-015-0044-8.pdf

D. 'ambrosio and D. , Regulatory T cells: How do they find their space in the immunological arena?, Seminars in Cancer Biology, vol.16, issue.2, pp.91-97, 2006.
DOI : 10.1016/j.semcancer.2005.11.002

K. Franciszkiewicz, A. Boissonnas, M. Boutet, and C. Combadiere, Role of Chemokines and Chemokine Receptors in Shaping the Effector Phase of the Antitumor Immune Response, Cancer Research, vol.72, issue.24, pp.6325-6332, 2012.
DOI : 10.1158/0008-5472.CAN-12-2027

N. Y. Hemdan, Anti-cancer versus cancer-promoting effects of the interleukin-17-producing T helper cells, Immunology Letters, vol.149, issue.1-2, pp.123-133, 2013.
DOI : 10.1016/j.imlet.2012.11.002

F. Sallusto, A. Lanzavecchia, and C. R. Mackay, Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses, Immunology Today, vol.19, issue.12, pp.568-574, 1998.
DOI : 10.1016/S0167-5699(98)01346-2

A. Viola, A. Sarukhan, V. Bronte, and B. Molon, The pros and cons of chemokines in tumor immunology, Trends in Immunology, vol.33, issue.10, pp.496-504
DOI : 10.1016/j.it.2012.05.007

G. Dranoff, Cytokines in cancer pathogenesis and cancer therapy, Nature Reviews Cancer, vol.7, issue.1, pp.11-22, 2004.
DOI : 10.1038/nm1001-1118

A. Mantovani, B. Savino, M. Locati, L. Zammataro, P. Allavena et al., The chemokine system in cancer biology and therapy, Cytokine & Growth Factor Reviews, vol.21, issue.1, pp.27-39, 2010.
DOI : 10.1016/j.cytogfr.2009.11.007

B. N. Bidwell, C. Y. Slaney, N. P. Withana, S. Forster, Y. Cao et al., Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape, Nature Medicine, vol.791, issue.8, pp.1224-1231, 2012.
DOI : 10.1093/nar/gkm013